logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Kevin J Tomaselli

This inventor holds 22 USPTO granted patents and 3 published patent applications, primarily in Apoptotic Proteases. Top assignees: Idun Pharmaceuticals, Inc., Ikaria Inc., Thomas Jefferson University. Active years: 1998-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin J Tomaselli. Retrieved from https://idiyas.com/inventor/kevin-j-tomaselli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 22 

% Patents Active = 68.2

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 66(Granted Patents)


Location History:

  • La Jolla, CA (US) (1998 - 2004)
  • San Diego, CA (US) (2001 - 2012)

Company Filing History:

goldMedal15 out of 33 
 
Idun Pharmaceuticals, Inc.
 patents
silverMedal2 out of 7 
 
Ikaria Inc.
 patents
bronzeMedal1 out of 539 
 
Thomas Jefferson University
 patents
4. 5 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2012

Loading Chart...
Areas of Expertise:
Apoptotic Proteases
Cysteine Proteases
Liquid Chalcogenides
Interleukin-1 Converting Enzyme
Inflammation Treatment
MCH4 Polypeptide
MCH5 Polypeptide
Nucleic Acids Encoding
Cellular Apoptosis
Disease Treatment
Rapid Identification Methods
22 patents (USPTO):Explore Patents
1. 8226986 - Liquid chalcogenide compositions and methods of manufacturing and using the same (2012-07-24),
2. 7923037 - Liquid chalcogenide compositions and methods of manufacturing and using the same (2011-04-12),
3. 6969703 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2005-11-29),
4. 6897296 - Antibody that specifically binds an Mch5 polypeptide (2005-05-24),
5. 6790989 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2004-09-14),
6. 6730779 - Antibody that specifically binds an Mch4 polypeptide (2004-05-04),
7. 6716960 - Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use (2004-04-06),
8. 6693096 - Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2004-02-17),
9. 6686459 - Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use (2004-02-03),
10. 6610683 - Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-08-26),
11. 6531467 - Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-11),
12. 6528506 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-04),
13. 6525024 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2003-02-25),
14. 6518032 - Rapid methods for identifying modifiers of cellular apoptosis activity (2003-02-11),
15. 6515173 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2003-02-04),

Title: Kevin J. Tomaselli: A Pioneer in Chalcogenide Innovations

Introduction

Kevin J. Tomaselli, based in San Diego, CA, has made significant contributions to the field of material science, particularly through his innovative patents and research. With a total of 22 patents to his name, Tomaselli stands out as a prominent inventor dedicated to tackling complex challenges in health and biotechnology.

Latest Patents

Among his recent innovations, Tomaselli has developed a groundbreaking patent titled "Liquid Chalcogenide Compositions and Methods of Manufacturing and Using the Same." This invention presents novel, stable liquid compositions comprising chalcogenides or salts thereof. These compositions have the potential to be transformative in various applications, including the treatment and prevention of ischemic or hypoxic injuries and the preservation of biological matter. His work represents a significant step forward in leveraging chalcogenides for practical uses.

Career Highlights

Throughout his career, Tomaselli has built a strong foundation in research and development, which is evident from his extensive patent portfolio. He has worked with reputable organizations such as Idun Pharmaceuticals, Inc., where he contributed to innovative projects that align with his expertise in chalcogenide materials.

Collaborations

Tomaselli's journey in the field has also been marked by collaboration with eminent professionals. Notably, he has worked alongside Robert Craig Armstrong and Lawrence C. Fritz, both of whom have made substantial contributions in their respective domains. These partnerships highlight the collaborative nature of scientific research, leading to advances that often redefine industry standards.

Conclusion

Kevin J. Tomaselli's work in the field of chalcogenide compositions reflects his deep commitment to innovation and advancement in biotechnology. With a promising patent portfolio and collaborations with leading professionals, he continues to pave the way for new methodologies aimed at improving medical treatments and biological preservation. His contributions not only address pressing scientific questions but also set a benchmark for future research in material sciences.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…